CD24 shows early upregulation and nuclear expression but is not a prognostic marker in colorectal cancer

Journal of Clinical Pathology

Volumn 62, Issue 12, 2009, Pages 1117-1122

  Ahmed, M A H ^a,b   Al Attar, A ^a   Kim, J ^c   Watson, N F S ^a   Scholefield, J H ^a   Durrant, L G ^a   Ilyas, M ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Suez Canal University Faculty of Medicine   (Egypt)

^c The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD24 ANTIGEN; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY; TISSUE SECTION; UPREGULATION;

ADENOMA; AGED; AGED, 80 AND OVER; ANTIGENS, CD24; ANTIGENS, NEOPLASM; CELL NUCLEUS; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 73449137612     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2009.069310     Document Type: Article

References (25)

1. Anon. CancerStats Key Facts on Bowel Cancer website. http://info. cancerresearchuk.org/cancerstats/types/bowel/ (accessed 1 Jun 2009).
2. Morris EJ, Maughan NJ, Forman D, et al. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology. Gut 2007;56:1419-25.
3. Poncet C, Frances V, Gristina R, et al. CD24, a glycosylphosphatidylinositol-anchored molecule, is transiently expressed during the development of human central nervous system and is a marker of human neural cell lineage tumors. Acta Neuropathol 1996;91:400-8.
4. Lu LW, Smithson G, Kincade PW, et al. Two models of murine B lymphopoiesis: a correlation. Eur J Immunol 1998;28:1755-61.
5. Jackson D, Waibel R, Weber E, et al. CD24, a signal-transducing molecule expressed on human b-cells, is a major surface-antigen on small-cell lung carcinomas. Cancer Res 1992;52:5264-70.
6. Kristiansen G, Denkert C, Schluns K, et al. CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 2002;161:1215-21.
7. Kristiansen G, Schluns K, Yongwei Y, et al. CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 2003;88:231-6.
8. Kristiansen G, Winzer KJ, Mayordomo E, et al. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003;9:4906-13.
9. Kristiansen G, Pilarsky C, Pervan J, et al. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004;58:183-92.
10. Agrawal S, Kuvshinoff BW, Khoury T, et al. CD24 expression is an independent prognostic marker in cholangiocarcinoma. J Gastrointest Surg 2007;11:445-51.
11. Chou YY, Jeng YM, Lee TT, et al. Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol 2007;14:2748-58.
12. Lee HJ, Kim DI, Kwak C, et al. Expression of CD24 in clear cell renal cell carcinoma and its prognostic significance. Urology 2008;72:603-7.
13. Aigner S, Sthoeger ZM, Fogel M, et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood 1997;89:3385-95.
14. Aigner S, Ramos CL, Hafezi-Moghadam A, et al. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J 1998;12:1241-51.
15. Li CW, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-7.
16. Weichert W, Denkert C, Burkhardt M, et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005;11:6574-81.
17. Sagiv E, Memeo L, Karin A, et al. CD24 is a new oncogene, early at the multistep process-of colorectal cancer carcinogenesis. Gastroenterology 2006;131:630-9.
18. Weichert W, Denkert C, Burkhardt M, et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res 2005;11:6574-81.
19. Sagiv E, Kazanov D, Arber N. CD24 plays an important role in the carcinogenesis process of the pancreas. Biomed Pharmacother 2006;60:280-4.
20. Shulewitz M, Soloviev I, Wu T, et al. Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer. Oncogene 2006;25:4361-9.
21. Ullenhag GJ, Mukherjee A, Watson NFS, et al. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 2007;13:5070-5.
22. Cregger M, Berger AJ, Rimm DL. Immunohistochemistry and quantitative analysis of protein expression. Arch Pathol Lab Med 2006;130:1026-30.
23. Liao YC, Chen NT, Shih YP, et al. Up-regulation of C-terminal tensin-like molecule promotes the tumorigenicity of colon cancer through beta-catenin. Cancer Res 2009;69:4563-6.
24. Choi D, Lee HW, Hur KY, et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009;15:2258-64.
25. Choi YL, Xuan YH, Lee SJ, et al. Enhanced CD24 expression in colorectal cancer correlates with prognostic factors. Korean J Pathol 2006;40:103-11.